Assessment of Food and Drug Administration– and European Medicines Agency–Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life

Comparative Assessment of Clinical Benefit Using the ESMO-Magnitude of Clinical Benefit Scale Version 1.1 and the ASCO Value Framework Net Health Benefit Score

(2019) Nathan I. Cherny et al.   JOURNAL OF CLINICAL ONCOLOGY

Assessment of Whether the American Society of Clinical Oncology’s Value Framework and the European Society for Medical Oncology’s Magnitude of Clinical Benefit Scale Measure Absolute or Relative Clinical Survival Benefit

(2019) Ronak Saluja et al.   JAMA Oncology

Understanding the Minimal Clinically Important Difference (MCID) of Patient-Reported Outcome Measures

(2019) Ahmad R. Sedaghat   OTOLARYNGOLOGY-HEAD AND NECK SURGERY

Are Surrogate Endpoints Unbiased Metrics in Clinical Benefit Scores of the ASCO Value Framework?

(2019) Sierra Cheng et al.   Journal of the National Comprehensive Cancer Network

Examining Trends in Cost and Clinical Benefit of Novel Anticancer Drugs Over Time

(2018) Ronak Saluja et al.   Journal of Oncology Practice

Unknown

(2018)   CANCER

Impact of Patient- and Clinician-Reported Cumulative Toxicity on Quality of Life in Patients With Metastatic Castration-Naïve Prostate Cancer

(2018) Claudia S.E.W. Schuurhuizen et al.   Journal of the National Comprehensive Cancer Network

Minimal important difference to infer changes in health-related quality of life—a systematic review

(2017) Ravishankar Jayadevappa et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Do the American Society of Clinical Oncology Value Framework and the European Society of Medical Oncology Magnitude of Clinical Benefit Scale Measure the Same Construct of Clinical Benefit?

(2017) Sierra Cheng et al.   JOURNAL OF CLINICAL ONCOLOGY

Do cancer drugs improve survival or quality of life?

(2017) Vinay Prasad   BMJ-British Medical Journal

Do cancer drugs improve survival or quality of life?

(2017) Vinay Prasad   BMJ-British Medical Journal

Assessment of Overall Survival, Quality of Life, and Safety Benefits Associated With New Cancer Medicines

(2017) Sebastian Salas-Vega et al.   JAMA Oncology

Does severe toxicity affect global quality of life in patients with metastatic colorectal cancer during palliative systemic treatment? A systematic review

(2016) C.S.E.W. Schuurhuizen et al.   ANNALS OF ONCOLOGY

Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received

(2016) Lowell E. Schnipper et al.   JOURNAL OF CLINICAL ONCOLOGY

Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a start in setting international standards

(2016) Andrew Bottomley et al.   LANCET ONCOLOGY

Inclusion of patient-reported outcome measures in registered clinical trials: Evidence from ClinicalTrials.gov (2007–2013)

(2015) E. Vodicka et al.   Contemporary Clinical Trials

Cancer Drugs Approved on the Basis of a Surrogate End Point and Subsequent Overall Survival

(2015) Chul Kim et al.   JAMA Internal Medicine

Progression-free survival as an end-point in solid tumours – Perspectives from clinical trials and clinical practice

(2014) Andrew G. Robinson et al.   EUROPEAN JOURNAL OF CANCER

Minimal Clinically Important Difference

(2014) Anna E. McGlothlin et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Unintended Consequences of Expensive Cancer Therapeutics—The Pursuit of Marginal Indications and a Me-Too Mentality That Stifles Innovation and Creativity

(2014) Tito Fojo et al.   JAMA Otolaryngology-Head & Neck Surgery

Review of Oncology and Hematology Drug Product Approvals at the US Food and Drug Administration Between July 2005 and December 2007

(2010) R. Sridhara et al.   JNCI-Journal of the National Cancer Institute